Vaxcyte (PCVX) Asset Writedowns and Impairment (2020 - 2022)
Vaxcyte (PCVX) posted quarterly Asset Writedowns and Impairment of -$13000.0 for Q4 2022, down 108.33% quarter-over-quarter from $156000.0 in Q2 2022.
Powered by 
Analysis
Vaxcyte (PCVX) Asset Writedowns and Impairment (2020 - 2022) Analysis & Trends
Vaxcyte (PCVX) has reported Asset Writedowns and Impairment for 1 consecutive years, with -$13000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Asset Writedowns and Impairment changed N/A year-over-year to -$13000.0; the TTM figure through Sep 2023 stood at -$13000.0 (down 106.1% YoY), while the FY2022 annual figure was $200000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment retreated to -$13000.0 in Q4 2022 per PCVX's latest filing, from $156000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $156000.0 in Q2 2022 and bottomed at -$13000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.83 Bn | 8.83 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 156,000.00 |
| Mar 31, 2022 | 57,000.00 |
| Dec 31, 2020 | 33,000.00 |